0000950170-24-030311.txt : 20240312
0000950170-24-030311.hdr.sgml : 20240312
20240312200443
ACCESSION NUMBER: 0000950170-24-030311
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240309
FILED AS OF DATE: 20240312
DATE AS OF CHANGE: 20240312
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Machatha Stephen
CENTRAL INDEX KEY: 0001836354
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36332
FILM NUMBER: 24744161
MAIL ADDRESS:
STREET 1: 131 HARTWELL AVENUE
STREET 2: SUITE 320
CITY: LEXINGTON
STATE: MA
ZIP: 02421
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Aldeyra Therapeutics, Inc.
CENTRAL INDEX KEY: 0001341235
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 131 HARTWELL AVENUE
STREET 2: SUITE 320
CITY: LEXINGTON
STATE: MA
ZIP: 02421
BUSINESS PHONE: 781-761-4904
MAIL ADDRESS:
STREET 1: 131 HARTWELL AVENUE
STREET 2: SUITE 320
CITY: LEXINGTON
STATE: MA
ZIP: 02421
FORMER COMPANY:
FORMER CONFORMED NAME: Aldexa Therapeutics, Inc.
DATE OF NAME CHANGE: 20130102
FORMER COMPANY:
FORMER CONFORMED NAME: Neuron Systems Inc
DATE OF NAME CHANGE: 20051012
4
1
ownership.xml
4
X0508
4
2024-03-09
0001341235
Aldeyra Therapeutics, Inc.
ALDX
0001836354
Machatha Stephen
C/O ALDEYRA THERAPEUTICS, INC.
131 HARTWELL AVENUE
LEXINGTON
MA
02421
false
true
false
false
Chief Development Officer
false
Common Stock
2024-03-11
4
S
false
18231
3.4064
D
255032
D
Common Stock
2024-03-12
4
S
false
11537
3.164
D
243495
D
Common Stock
211
I
See footnote
Stock Option (right to buy)
3.62
2024-03-09
4
A
false
405450
0.00
A
2034-03-08
Common Stock
405450
405450
D
These shares of common stock were automatically sold in a non-discretionary transaction by the Reporting Person in order to cover tax withholding obligations upon the settlement of certain time-based restricted stock unit awards.
Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $3.27 to $3.58. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range.
These shares of common stock were sold by the Reporting Person for tax withholding and tax planning purposes in connection with the settlement of certain time-based restricted stock unit awards.
Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $3.11 to $3.31. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range.
These shares are held directly by the Reporting Person's spouse. The Reporting Person disclaims beneficial ownership over these shares for purposes of Section 16 or for any other purposes.
The shares subject to this option shall vest in equal monthly installments over the next 48 months of continuous service to the Issuer after January 1, 2024.
/s/ Stephen Machatha
2024-03-12